Test Code RNP RNP Antibodies, IgG, Serum
Additional Codes
Mayo Test ID |
---|
RNP |
Reporting Name
RNP Ab, IgG, SUseful For
Evaluating patients with signs and symptoms of a connective tissue disease in whom the test for antinuclear antibodies is positive
Testing for ribonucleoprotein particle antibodies is not useful in patients without demonstrable antinuclear antibodies.
Testing Algorithm
For more information see Connective Tissue Disease Cascade.
Performing Laboratory
Mayo Clinic Laboratories in RochesterSpecimen Type
SerumSpecimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Specimen Minimum Volume
0.35 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 21 days | |
Frozen | 21 days |
Special Instructions
Reference Values
<1.0 U (negative)
≥1.0 U (positive)
Reference values apply to all ages.
Day(s) Performed
Monday through Saturday
Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
86235
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
RNP | RNP Ab, IgG, S | 29958-6 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
RNP | RNP Ab, IgG, S | 29958-6 |
Interpretation
A positive result for anti-ribonucleoprotein particle 68/A (RNP68/A) antibodies in association with positivity of antinuclear antibodies may be consistent with a diagnosis of connective tissue disease.
Clinical Reference
1. Tanaka Y, Kuwana M, Fujii T, et al. 2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases. Mod Rheumatol. 2021;31(1):29-33
2. Hoffmann-Vold AM, Gunnarsson R, Garen T, Midtvedt O, Molberg O. Performance of the 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis (SSc) in large, well-defined cohorts of SSc and mixed connective tissue disease. J Rheumatol. 2015;42(1):60-63
3. Mattioli M, Reichlin M. Characterization of a soluble nuclear ribonucleoprotein antigen reactive with SLE sera. J Immunol. 1971;107(5):1281-1290
4. Combe B, Rucheton M, Graafland H, Lussiez V, Brunel C, Sany J. Clinical significance of anti-RNP and anti-Sm autoantibodies as determined by immunoblotting and immunoprecipitation in sera from patients with connective tissue diseases. Clin Exp Immunol. 1989;75(1):18–24
5. Ihn H, Yamane K, Yazawa N, et al. Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis. Clin Exp Immunol. 1999;117(2):383-387
6. Pattersson I, Wang G, Smith EI, et al. The use of immunoblotting and immunoprecipitation of (U) small nuclear ribonucleoproteins in the analysis of sera of patients with mixed connective tissue disease and systemic lupus erythematosus: across-sectional, longitudinal study. Arthritis Rheum. 1986;29(8): 986-996
7. Satoh M, Krzyszczak ME, Li Y, et al. Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: a retrospective clinical study. Arthritis Res Ther. 2011;13(3):R73
8. Betteridge Z, Tansley S, Shaddick G, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019;101:48-55
9. Tebo AE, Peterson LK, Snyder MR, Lebiedz-Odrobina D. Clinical Significance of Anti-U1 Ribonucleoprotein Antibody Is Analyte Dependent: Implications for Laboratory Reporting, Interpretation, and Interassay Correlations. Arch Pathol Lab Med. 2023;147(12):1461-1465
Report Available
1 to 3 daysMethod Name
Multiplex Flow Immunoassay